

Dinutuximab

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



Not qualified for an ESMO-MCBS credit



**Serious and disabling adverse effects**



**Other adjustments**



Dinutuximab

### SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Brain Tumours  
 Therapeutic Indication: <32 years old with high-risk neuroblastoma after remission and stem cell transplantation  
 Experimental Arm: Dinutuximab + Cis retinoic acid+GMCSF+IL2  
 Control Arm: Cis retinoic acid

